Clorgyline

Clorgyline is a small-molecule drug belonging to the monoamine oxidase inhibitor (MAOI) class, and more specifically to the acetylenic inhibitors related to pargyline ^[1]. It acts on monoamine oxidase, an enzyme found in the brain and other tissues that degrades monoamine neurotransmitters, and it is selective for the subtype known as monoamine oxidase A, binding to it irreversibly ^[1][2]. Because the block is permanent, the enzyme's activity recovers only as the body makes fresh molecules of it ^[2].

The compound emerged from mid-twentieth-century research into antidepressant drugs and was investigated for that purpose, but it was never marketed as a medicine ^[1]. Its lasting importance is as a pharmacological probe: studies with clorgyline demonstrated that monoamine oxidase is not a single enzyme but comes in two forms, a clorgyline-sensitive type A and a clorgyline-resistant type B, a distinction that reshaped how researchers understood the metabolism of neurotransmitters and guided the later development of selective MAO inhibitors ^[1][2].

In neuroscience research, clorgyline is used to selectively switch off monoamine oxidase A in laboratory experiments, which raises brain levels of serotonin, noradrenaline and dopamine and lets scientists study the consequences ^[2][3]. Prolonged exposure has been shown to trigger adaptive changes in the brain, such as a reduction in the number and responsiveness of certain noradrenaline receptors, an observation that connects MAO-A inhibition to the receptor adaptations thought to accompany antidepressant action ^[2]. Beyond the nervous system, clorgyline has been explored for unrelated purposes; for example, it can inhibit the molecular pumps that fungi use to expel drugs, and in the laboratory it reversed resistance to antifungal azoles in Candida strains ^[4]. It has also been used in animal studies of feeding and body weight ^[5].

Clorgyline is not entirely specific to monoamine oxidase. It binds with high affinity to sigma receptors ^[3] and to imidazoline binding sites ^[1], and it can inhibit several drug-transport pumps ^[4], so its full pharmacological profile extends beyond enzyme inhibition. These additional actions are of interest mainly to researchers rather than in any clinical setting, since the drug is not used therapeutically ^[1].

Because it was never approved or marketed, clorgyline has no consumer or medical product forms and exists essentially as a laboratory reagent; as an irreversible MAO-A inhibitor it would, like clinically used MAOIs, be expected to interact dangerously with tyramine-rich foods and with serotonergic drugs, which is one reason such nonselective and type-A-selective inhibitors have largely been superseded ^[1][2].

This is the dangerous end of MAO inhibition. Blocking MAO-A in the gut means tyramine-rich foods can cause a hypertensive crisis, and combining it with serotonergic drugs risks serotonin syndrome; both are the classic MAOI hazards. It is not an approved medicine and is handled as a research chemical. Treat it with the same respect as any irreversible MAO-A inhibitor.